New study sheds light on the role of α2,6-sialylation in Alzheimer’s disease
Peer-Reviewed Publication
In honor of Alzheimer's Awareness Month, we’re exploring the science and stories surrounding Alzheimer’s disease.
Updates every hour. Last Updated: 30-Oct-2025 18:11 ET (30-Oct-2025 22:11 GMT/UTC)
A new study published in Engineering offers fresh insights into Alzheimer’s disease, revealing that inhibiting an enzyme called ST6Gal-I can reduce levels of BACE1 and amyloid-β plaques, which are key factors in the disease’s progression. This research underscores the potential of targeting glycosylation pathways as a strategy for developing new treatments for Alzheimer’s.
Scientists at the USC Leonard Davis School of Gerontology have discovered a key connection between high levels of iron in the brain and increased cell damage in people who have both Down syndrome and Alzheimer’s disease. In the study, researchers found that the brains of people diagnosed with Down syndrome and Alzheimer’s disease (DSAD) had twice as much iron and more signs of oxidative damage in cell membranes compared to the brains of individuals with Alzheimer’s disease alone or those with neither diagnosis. The results point to a specific cellular death process that is mediated by iron, and the findings may help explain why Alzheimer’s symptoms often appear earlier and more severely in individuals with Down syndrome.
Three dimensional immunohistochemistry (3D-IHC) reveals spatial and molecular details of biological tissues, but current methods are slow and limited in depth. Researchers from Japan have developed a fast, high-sensitivity 3D-IHC method using nanobodies fused with peroxidase and a novel signal amplification system. Their technique labels neurons and glia in 1-mm-thick brain tissue within three days, offering a powerful new tool for neuroscience and disease research, including Alzheimer’s pathology.
“Although it is known that Alzheimer’s disease can start up to 20 years before the first symptoms appear, the lack of knowledge about how it progresses prevents the development of effective treatments, as well as a clear diagnosis to confront this neurodegenerative disease, which origin is also unknown.” This is pointed out by the researcher at the UMA David Baglietto, specializing in the study of risk factors –namely, genetic, environmental and lifestyle– influencing on the onset and progression of this pathology.
A straightforward nightly activity may act as a memory-boosting tool, a new study has revealed.